Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 14/20 | 0.38 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5641069 | 0.89 | ENPP2 (0.37) | ENPP2LMNATP53MAPTDRD4 | |
| SCHEMBL5640611 | 0.84 | TAS1R3 (0.40) | LMNATP53MAPTCFTR | |
| SCHEMBL5641674 | 0.84 | BCHE (0.42) | ENPP2LMNATP53DRD4 | |
| SCHEMBL5642492 | 0.83 | TP53 (0.45) | ENPP2LMNATP53MAPTDRD4 | |
| SCHEMBL5639534 | 0.83 | BCHE (0.41) | ENPP2LMNATP53MAPTDRD4 | |
| SCHEMBL4586428 | 0.82 | KCNH2 (0.47) | LMNATP53DRD4 | |
| SCHEMBL5639513 | 0.80 | BCHE (0.37) | ENPP2LMNATP53MAPT | |
| SCHEMBL4587973 | 0.80 | DRD4 (0.39) | ENPP2DRD4 | |
| SCHEMBL4587789 | 0.79 | BCHE (0.37) | LMNAMAPT | |
| SCHEMBL4587510 | 0.79 | CCR3 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667647-A4 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1667647-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | disclosed |
| WO-2005032468-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | F2, F12, SPINT2 | ENPP2 1882/4885HSF1 2376/4885LMNA 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.